TCT 2009 Press Conference Schedule

Wednesday, September 23

9:30 am-10:30 am

Room: 300
Moderator: Alexandra J. Lansky, MD
Discussants: Andrea Abizaid, MD, PhD; Stephen G. Ellis, MD; Ian T. Meredith, MBBS, PhD, FACC, FRACP; Jeffrey J. Popma, MD

• SPIRIT IV: A Prospective Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents
  Gregg W. Stone, MD
• FAME: Two-Year Follow-up from a Prospective Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease
  William F. Fearon, MD
• ISAR-DESIRE 2: A Prospective Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Sirolimus-Eluting Stent Restenosis
  Robert A. Byrne, MB BCh
• SIRTAX-LATE: Five-Year Clinical and Angiographic Follow-up from a Prospective Randomized Trial of Paclitaxel-Eluting and Sirolimus-Eluting Stents
  Lorenz Räber
• LEADERS: Two-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
  Klauss Volker
• COMPARE: A Prospective Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents
  Peter C. Smits, MD, PhD

Thursday, September 24

9:00 am-10:00 am

Room: 300
Moderator: Roxana Mehran, MD
Discussants: Ted Feldman, MD; Ajay J. Kirtane, MD, SM; David F. Kong, MD; Ron Waksman, MD

• TRITON-TIMI 38 ECONOMIC SUBSTUDY: Cost-Effectiveness of Prasugrel vs. Clopidogrel from a Prospective Randomized Trial of Patients with ACS Undergoing PCI
  David J. Cohen, MD
• CURRENT-PCI OASIS 7: A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS
  Shamir R. Mehta, MD, MSc
• PROSPECT: A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque
  Gregg W. Stone, MD
• COGENT: A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel
  Deepak L. Bhatt, MD, MPH
• CHARISMA GENOMICS SUBSTUDY: Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention
  Deepak L. Bhatt, MD, MPH
• PLATO INVASIVE: A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy
  Christopher P. Cannon, MD

Friday, September 25

9:30 am-10:30 am

Room: 300
Moderator: Ajay J. Kirtane, MD, SM
Discussants: William A. Gray, MD; Liliana R. Grinfeld, MD; Barry T. Katzen, MD; Mark Reisman, MD

• SYMPLICITY 1:  One-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension
  Henry Krum
• DEBATER: A Prospective Randomized Trial of Drug-Eluting vs. Bare-Metal Stents With or Without Abciximab in STEMI
  Rolf Michels
• BCIS-1: A Prospective Randomized Trial of Intra-Aortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI
  Simon Redwood, MD
• FAUST: A Prospective Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access
  Arnold Seto, MD, MPA
• NORDIC-BALTIC BIFURCATION STUDY III: A Prospective Randomized Trial of Side Branch Dilatation Strategies in Patients with Coronary Bifurcation Lesions Undergoing Treatment with a Single Stent
  Matti Jaakko Niemela, MD
• HORIZONS-AMI: Two-Year Follow-up from a Prospective Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare-Metal Stents in STEMI
  Roxana Mehran, MD